☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Everest
Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerati...
May 25, 2022
Pfizer Report Results of Etrasimod in P-III (ELEVATE UC 52) Study for the Treatment of Ulcerative Colitis
March 30, 2022
Everest Licensing Partner Venatorx Report Results of Cefepime-Taniborbactam in P-III (CERTAIN-1) Study for Complicated Urinary Tra...
March 10, 2022
PharmaShots Weekly Snapshots (September 20 - 24, 2021)
September 24, 2021
Load more...
Back to Home
